Twist Bioscience posts record quarterly revenue, raises full-year guidance
The company reported $118.4 million in fiscal third-quarter revenue and raised its fiscal 2026 revenue outlook to $456-$457 million.
Twist Bioscience Corporation reported financial results for the third quarter of fiscal 2026, ended June 30, 2026, on August 3, 2026. Revenue reached $118.4 million, an increase of more than 23% over $96.1 million in the third quarter of fiscal 2025, marking the 14th consecutive quarter of sequential growth.1
By segment, DNA Synthesis and Protein Solutions revenue grew 39% to $56.6 million compared to $40.8 million a year earlier, and grew 6% sequentially from $53.3 million in the second quarter of fiscal 2026.1 NGS Applications revenue grew 12% to $61.8 million compared to $55.3 million a year earlier, and grew 8% sequentially from $57.4 million in the second quarter.1
Gross margin for the quarter was 52.8%, up sequentially from 51.6% in the second quarter of fiscal 2026.1 Net loss for the quarter was $35.1 million, or $0.56 per diluted share, compared to net income of $20.4 million, or $0.33 per diluted share, a year earlier, which had included a gain of $48.8 million from the spin out of Atlas Data Storage.1 Adjusted EBITDA was $(11.3) million compared to $(8.0) million in the same period of fiscal 2025.1
On guidance, Twist raised its full fiscal 2026 revenue outlook to a range of $456 million to $457 million, growth of approximately 21% year over year, up from prior guidance of $442 to $447 million.1 For the fourth quarter, the company expects total revenue of approximately $123 million to $124 million, growth of about 25% year over year at the midpoint, with sequential growth in both segments, and expects to achieve adjusted EBITDA breakeven.1
On cash, as of June 30, 2026, the company had approximately $167 million in cash, cash equivalents and short-term investments.1
Among operational highlights, the Twist Comprehensive Viral Research Panel enabled researchers in the Democratic Republic of the Congo to identify a rare strain of Ebola that PCR tests had missed.1 The company also launched Twist Complex Genes commercially for broad access following an early access period.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.